Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies

UCB is the latest biopharma player to consummate a multibillion-dollar deal amid a surge in biotech M&A activity, acquiring Ken Song’s Candid Therapeutics, one of the leading T cell engager companies. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the $2 billion takeout and the opportunity in the TCE space.They also assess the drug development landscape for leukodystrophies and the market for biotech IPOs on NASDAQ, where a trio of biotechs exceeded expectations last week, lifting hopes that the window for new listings is broadening. Looking ahead to June, the analysts also preview the third BioCentury Grand Rounds U.S. conference. This episode of the BioCentury This Week podcast was brought to you by Jeito Capital.View full story: https://www.biocentury.com/article/659365#BiotechMA #TCellEngagers #Leukodystrophy #BiotechIPO #TranslationalScience00:01 - Sponsor Message: Jeito Capital02:19 - Grand Rounds Seattle12:47 - UCB’s Candid Buy20:27 - Leukodystrophies Pipeline27:22 - Biotech IPOsTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text